GlassScriptPhysician profile
Marian Kamath
NPI 1184652356
$15,215.01
in general payments reported to CMS, 2019-2025
59 companies · $3,049 in 2025
The $3,049 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,685 · 2020: $1,024 · 2021: $2,163 · 2022: $2,155 · 2023: $2,678 · 2024: $2,462 · 2025: $3,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,188.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,116.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,406.47 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,079.58 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,029.68 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $802.89 | 2019-2025 | |
| Amgen INC. | $731.04 | 2019-2025 | Krystexxa, Repatha, Repatha |
| Paratek Pharmaceuticals, INC. | $678.00 | 2021-2025 | Nuzyra, Xhance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $657.69 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $606.26 | 2022-2025 | Rexulti |
| Mannkind Corporation | $596.52 | 2022-2025 | Afrezza |
| Lilly USA, LLC | $481.71 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Regeneron Healthcare Solutions, INC. | $457.56 | 2023-2025 | Dupixent, Evkeeza |
| Allergan, INC. | $443.09 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $375.93 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $340.87 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marian Kamath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.